Jae Park, MD, reviews the current treatment landscape and emerging options for treating adults with relapsed/refractory B-cell acute lymphoblastic leukemia
June 28th 2022
Jae Park, MD, shares an overview of available therapeutic options for patients with R/R B-ALL.
An oncologist specializing in the treatment of patients with B-ALL discusses the study design, efficacy, safety, and two-year updated results of the phase I/II ZUMA-3 study evaluating brexucabtagene autoleucel in adult patients with R/R B-ALL.
Dr. Jae Park comments on the findings from the ELIANA study and tisagenlecleucel as a potential option for adults with R/R B-ALL.
Practical considerations for treatment selection in patients who progress on CAR T-Cell therapy.